Multidrug resistance protein 2 (MRP2, ABCC2) is an efflux membrane transporter highly expressed in liver, kidney and intestine with important physiological and pharmacological roles. The goal of this study was to investigate the functional significance of promoter region polymorphisms in ABCC2 and potential allele-specific expression. Twelve polymorphisms in the 1.6 kb region upstream of the translation start site were identified by resequencing 247 DNA samples from ethnically diverse individuals. Luciferase reporter gene assays showed that ABCC2 À24C4T both alone and as part of a common haplotype (À24C4T/ À1019A4G/À1549G4A) increased promoter function 35% compared with the reference sequence (Po0.0001). No other common variants or haplotypes affected ABCC2 promoter activity. Allele-specific expression was also investigated as a mechanism to explain reported associations of the synonymous ABCC2 3972C4T variant with pharmacokinetic phenotypes. In Caucasian liver samples (n ¼ 41) heterozygous for the 3972C4T polymorphism, the 3972C allele was preferentially transcribed relative to the 3972T allele (Po0.0001). This allelic imbalance was particularly apparent in samples with haplotypes containing two or three promoter/untranslated region variants (À1549G4A, À1019A4G and À24C4T). The observed allelic imbalance was not associated with hepatic or renal ABCC2 mRNA expression. Additional mechanisms will need to be explored to account for the interindividual variation in ABCC2 expression and MRP2 function.
INTRODUCTION
The multidrug resistance protein 2 (MRP2), encoded by ABCC2, is a member of the ATP-binding cassette (ABC) family of membrane transporters. MRP2 is predominantly expressed in the canalicular membrane of hepatocytes, but can also be detected in the apical membranes of renal proximal tubule and intestinal epithelial cells. 1, 2 MRP2 has an important role in the pharmacokinetics of a wide variety of compounds. This transporter drives energy-dependent efflux of organic anions, often conjugated to glutathione, glucuronic acid or sulfate, into the bile or urine for elimination. It can also transport neutral or basic compounds, but requires glutathione for co-transport. 3, 4 MRP2 substrates include endogenous compounds such as glutathione, leukotriene C 4 , 17b-D-estradiol glucuronide and the heme metabolite bilirubin glucuronide as well as xenobiotics such as the 3-hydroxy-3methyl-glutaryl-coenzyme A reductase inhibitor pravastatin, and the anticancer drugs irinotecan and its glucuronide metabolite SN-38 glucuronide, cisplatin and methotrexate. 5, 6 The importance of MRP2-mediated transport has been clearly demonstrated in mutant rat models lacking Mrp2 expression 1 and in Dubin--Johnson syndrome patients with a hereditary deficiency of MRP2 caused by rare mutations in the coding region of ABCC2. 5--7 Also, a number of common ABCC2 non-synonymous polymorphisms have been associated with alterations in ABCC2 mRNA expression and/or MRP2 function 8--12 as well as with drug toxicities. 13--15 The functional effects of ABCC2 coding region and promoter polymorphisms remain controversial. In particular, the mechanisms by which promoter and synonymous polymorphisms influence MRP2 expression are unclear. Currently, there is limited information about transcriptional regulation of human ABCC2. Several studies have characterized a region between 197 and 517 bases upstream from the translation start site with important basal promoter activity. 16--18 This region contains consensus sequences for a number of transcription factors, including the TATA box, the liver abundant CCAAT-enhancer-binding protein and HNF1/4. Single-nucleotide polymorphisms (SNPs) in the promoter region may alter transcriptional activity and contribute to interindividual variability in MRP2 expression and the pharmacokinetics of MRP2 substrates.
To date, a number of SNPs have been associated with the pharmacokinetics, efficacy and toxicity of MRP2 substrates, although most findings have not been replicated. 19--22 For example, the ABCC2 À24C4T polymorphism has been shown to decrease, 10,19--21 increase 8 as well as have no effect on ABCC2 expression. 23--25 Interestingly, the ABCC2 synonymous variant 3972C4T, which is in linkage disequilibrium with a number of promoter region polymorphisms, was associated with exposure to irinotecan and its metabolite SN-38 glucuronide. 22, 26 Patients who were homozygous for the 3972T allele had higher area under the curves for irinotecan and SN-38 glucuronide compared with the combined group of patients having the CT or CC genotype.
The higher area under the curve is consistent with decreased activity and/or expression of MRP2. In contrast, other studies have shown no effect of this polymorphism on ABCC2 expression and MRP2 function. 9,10,27--29 This study represents a comprehensive functional analysis of genetic variants in the promoter region of ABCC2. Based on the reported associations of ABCC2 3972C4T with various phenotypes, 22, 30, 31 allele-specific expression was also investigated as a possible mechanism conferring functional significance for this synonymous SNP.
MATERIALS AND METHODS

Tissue samples
Two hundred human liver samples were provided by the Liver Tissue Procurement and Distribution System NIH Contract #N01-DK-9-2310 and by the Cooperative Human Tissue Network and were processed through Dr Mary Relling's laboratory at St Jude Children's Research Hospital (Memphis, TN, USA); these liver samples were genotyped and used for ABCC2 allelespecific expression experiments. Additional kidney (n ¼ 56) and liver (n ¼ 34) samples were provided by the Pharmacogenetics of Membrane Transporters tissue repository at the University of California San Francisco and were used to correlate ABCC2 3972C4T genotype with total ABCC2 mRNA expression.
Genetic analysis of the 5 0 -region of ABCC2
A collection of 247 ethnically diverse genomic DNA samples were obtained from the Coriell Institute of Medical Research (http://coriell.org). This collection of samples was used to screen for genetic variations in a 1.6 kb upstream region of ABCC2. Initial screening was done using PCR, denaturing high-performance liquid chromatography and direct sequencing as previously described. 32 Plasmid construction A 1.6 kb region upstream of the ABCC2 translation start site was PCR amplified from genomic DNA and subcloned into pCR2.1 using the standard protocol from the TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA). The amplified promoter DNA was digested with NheI and XhoI (New England Biolabs, Beverly, MA, USA) and was cloned into the reporter gene expression vector pGL4.11b (Promega, Madison, WI, USA), which contains a luciferase gene downstream from the multiple cloning site. Compared with the earlier generation pGL3 vectors, the pGL4 vectors are engineered with fewer consensus regulatory sequences and a synthetic gene, which has been codon optimized for mammalian expression. Individual nonsingleton variants or variants in haplotypes were introduced using specific primers ( Supplementary Table 1 ) and the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Plasmids were sequenced to verify the correct introduction of variants and were isolated as endotoxin-free preparations, a step that has been shown to eliminate purity bias and to significantly improve interassay variability.
Cell culture and reporter gene assay
HepG2 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. A day before transfection cells were counted and seeded on 96-well plates at a density of 5 Â 10 4 cells per well. pGL4.11b empty vector or plasmids containing either reference or variant sequences were transiently transfected together with Renilla luciferase vector into HepG2 cells using the Lipofectamine 2000 reagent (Invitrogen). Renilla luciferase vector served as a transfection efficiency control. Cells were incubated for 24 h at 37 1C in humidified atmosphere with 5% CO 2 , after which they were washed with phosphate-buffered saline and incubated with 80 ml of passive lysis buffer (Promega) at room temperature on a shaker for 30 min. Aliquots were analyzed for luciferase activity in a dual luciferase reporter assay on a GloMax 96 luminometer (Promega) according to the manufacturer's instructions. The activities of Firefly and Renilla luciferases were measured sequentially from each sample and both reporters yield linear assays with subattomole (o10 À18 ) sensitivities and no endogenous activity in the host cells.
Genotyping
Genomic DNA was genotyped using a 5 0 -nuclease assay 33 and direct sequencing. The ABCC2 5 0 -promoter variants À1549G4A (rs1885301) and À1019A4G (rs2804402), the untranslated region (UTR) variant À24C4T (rs717620), the coding region variant 1249G4A (rs2273697), the intron 26 variant À34T4C (rs17216177) and the synonymous variant 3972C4T (rs3740066) were genotyped in 200 liver samples. Briefly, PCR for direct sequencing was carried out after optimization using a GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA). Sequencing analysis was done on an ABI 3700 automated sequencer using the ABI PRISM BigDye system (Life Technologies Corporation, Carlsbad, CA, USA). For Taqman 5 0 -nuclease sequencing, PCR and sequencing were performed in one reaction using specific primers for the variant of interest, either by Assays-on-Demand (À24C4T and 3972C4T; Applied Biosystems) or Assays-by-Design (primer/probes in Supplementary Table 2 ). The ABCC2 3972C4T SNP was also genotyped in 56 liver and 34 kidney samples using the DMET TM array chip on an Illumina platform; the ABCC2 3972C4T SNP was tagged by rs7067971 SNP (r 2 ¼ 1.0). In all genotyping assays, SNPs were checked for deviations from reported minor allele frequencies and also for Hardy--Weinberg equilibrium.
Reverse transcription, PCR and single base extension
RNA from human liver samples heterozygous for the ABCC2 3972C4T SNP were selected for reverse transcription and further analysis. One microgram of RNA was reverse transcribed using the SuperScript II Reverse Transcriptase kit (Invitrogen) according to the manufacturer's protocol. Following reverse transcription, approximately 100 bp surrounding the 3972C4T SNP site was PCR amplified from the resulting complementary DNA and genomic DNA using specific primers. Excess dNTPs and primers were removed from the amplified product by incubating in shrimp alkaline phosphatase (Promega) and ExoI (New England Biolabs). PCR products then underwent single base extension using the SNaPshot mix (Applied Biosystems) and extension primers. Allele abundance was measured by an ABI 3700 sequencer. Peak heights of each allele were recorded from the resulting chromatogram.
Allele-specific expression analysis
An allelic imbalance ratio was quantified by the following equation:
where C 1 and G 1 are the peak heights of one allele in the complementary DNA and genomic DNA, respectively, and C 2 and G 2 are the peak heights of the second allele. The genomic DNA ratio was used as an internal normalization control to account for any fluorophore differences between the two alleles. To equalize the ratios in graphical space, the values were log transformed. Log-transformed values were defined as follows: log R ¼ 0, no preference for either allele; log R40, preference for allele 1; and log Ro0, preference for allele 2.
Quantifying mRNA expression in human liver and kidney samples ABCC2 mRNA expression was measured in 56 Caucasian kidney and 34 Caucasian liver samples using BioTrove Open Array technology according to the manufacturer's protocol (Life Technologies, Carlsbad, CA, USA). ABCC2 mRNA expression was normalized to a geometric mean of the expression of GAPDH, b-2 microglobin, and b-actin and expressed as 2 ÀDCt .
RESULTS
Polymorphisms in the proximal promoter region
To identify polymorphisms in the ABCC2 promoter region, a 1.6 kb region upstream from the ATG start site was sequenced from 247 ethnically diverse DNA samples from the Coriell Institute. Twelve polymorphisms were found in this region (Table 1) , including two SNPs in the 5 0 -UTR (À1 to À247 bp from the translation start site). All other SNPs were found 4700 bp upstream from the translation start site. An insertion was discovered at À1059 in a single chromosome in the African-American population. There were no variations found between À247 and À500 bp, the region required for basal expression. 7 Four polymorphisms (rs1885301, rs7910642, rs2804402 and rs717620) were considered cosmopolitan and were found at 45% frequency in each ethnic population. The À798C4A, À1059 þ G, À1292A4G and À1563G4A were rare and African-American specific. The À733G4A variant was specific to the Asian-American population, and the À23G4A UTR SNP was Pacific Islander specific. The non-singleton variants in the Caucasian, African-American and Asian-American populations were organized into eight different promoter haplotypes ( Table 2 ). In addition to the reference haplotype, a haplotype containing the À1549G4A, À1019A4G and À24C4T variants and a second containing only the À1023G4A variant were found at high frequencies in each of the ethnic groups. The combination of the À1549G4A and À1019A4G variants was common in Caucasians and African Americans (frequency of 12% and 26%, respectively) but not observed in the Asian-American population. Three African-American-specific haplotypes were identified, specifically À1549G4A/ À1292A4G/À1019A4G, 1549G4A/À1239G4A/À1019A4G and À1549G4A, at frequencies of 2%, 3% and 10%, respectively.
Effects of ABCC2 promoter variants on promoter activity in vitro
To assess if promoter polymorphisms have an effect on ABCC2 promoter activity, a 1.6 kb fragment was amplified from genomic DNA and cloned into the multiple cloning site of the promoterless luciferase plasmid, pGL4.11b. Single variant or promoter haplotypes were introduced by site-directed mutagenesis using specific primers. A plasmid containing the reference sequence showed approximately 70-fold higher activity than the promoterless pGL4.11b plasmid. The ABCC2 À24C4T SNP, when introduced both as a single variant and as part of the À24C4T/ À1019A4G/À1549G4A haplotype, showed a significant 35% increase in reporter activity compared with the reference ABCC2 promoter sequence (Po0.0001). Reporter activity of promoter constructs carrying other SNPs and haplotypes were not significantly different from the reference (Figure 1 ). There was no association of the common ABCC2 promoter variants (À1549A4G, À1023G4A and À24C4T) with ABCC2 mRNA levels in 34 Caucasian liver and 56 Caucasian kidney samples (data not shown).
Allele-specific expression
Allele-specific expression was investigated as a possible mechanism for observed associations of ABCC2 3972C4T with various phenotypes. 22, 30, 31 Of 200 liver samples available, the majority (n ¼ 137) were of known Caucasian descent and were used for this analysis. The sample sizes of other ethnic groups were too small for inclusion. Haplotypes were constructed using five additional polymorphisms commonly found with the 3972C4T variant and the distribution of these haplotypes in Caucasians is shown in Table 3 . Ten different haplotypes were estimated for the 137 liver samples. A total of 53 Caucasian liver samples were heterozygous at the 3972C4T polymorphic site. Seven livers carried lowfrequency haplotypes that were not considered further and five liver RNA samples could not be reverse transcribed and were also removed from the analysis. Results of the allele-specific expression analysis are presented for the most common haplotype pairs (n ¼ 41; Figure 2 ). Overall, there was a statistically significant preference for the 3972C allele compared with the 3972T allele (log ratios 40, Po0.0001). When examining haplotype pairs, H1/H2 (Po0.01), H2/H3 (Po0.0001) and H3/H4 (Po0.01) showed a significant preference for the C allele, suggesting that H2 and H4 might be driving this allelic imbalance. Samples carrying H2/H3 showed the highest mean C/T ratios of all haplotype combinations; in these samples, the C allele was 14% higher in abundance than the T allele.
Association of hepatic and renal ABCC2 mRNA expression with 3972C4T genotype
To assess if 3972C4T allelic imbalance is pronounced enough to affect total ABCC2 mRNA expression, we genotyped 34 additional Caucasian liver and 56 Caucasian kidney samples for this SNP using a tagging SNP (rs7067971) and quantified ABCC2 mRNA expression. No association was observed in these samples between 3972C4T genotype and ABCC2 mRNA expression ( Figure 3) .
DISCUSSION
MRP2 is one of the most important efflux transporters and can transport a large number of drugs and their conjugates. The ABCC2 gene encoding MRP2 is highly polymorphic and genetic variability is associated with interindividual differences in pharmacokinetics, drug response and toxicity. In particular, nonsynonymous coding region polymorphisms and disease mutations have been associated with changes in ABCC2 expression and/or MRP2 function. 8--14 The effects of ABCC2 promoter and synonymous variants are less well understood. The purpose of this study was twofold; first, to identify and characterize the functional effect of common variants in the ABCC2 promoter and 5 0 -UTR. In addition, studies were carried out to determine if allelic imbalance associated with the synonymous 3972C4T allele might provide mechanistic insight into the association of this variant with irinotecan disposition and toxicity. 22, 24, 29, 34 The proximal promoter region of ABCC2 has several common polymorphisms in the 1600 bp region upstream of the transcription start site. Interestingly, the region containing the core promoter (À300 to À500 bp) 16, 17 is devoid of any common genetic variation, consistent with a significant role in the constitutive regulation of ABCC2 expression. The most common promoter region haplotypes contain the À1549G4A and À1019G4A polymorphisms, often together with the À24C4T UTR variant. The association of À1549G4A, À1019G4A and À24C4T polymorphisms with increased irinotecan and/or SN-38 exposure following irinotecan treatment 22, 29, 34 suggests that these promoter region variants might influence ABCC2 transcription and therefore expression.
However, our in vitro studies failed to show a significant effect of the À1549G4A and À1019G4A variants, alone or in combination, with in vitro promoter activity. Interestingly, the À24C4T variant, ( -) 1 0 1 9 / 1 5 4 9 ( -) 2 4 / 1 0 1 9 / 1 5 4 9 ( -) 1 0 1 9 / 1 2 3 9 / 1 5 4 9 ( -) 1 0 1 9 / 1 2 9 2 / 1 5 4 9 Figure 1 . Functional activity of ABCC2 promoter variants. ABCC2 promoter activity was expressed as Firefly luciferase activity relative to Renilla luciferase activity; the activity of the reference sequence was set to one. Each column represents the mean±s.d. of four separate transfection experiments performed in triplicate. The positive control was a liver enhancer sequence. *Po0.001, significantly different from reference. alone and combined with the À1549G4A and À1019G4A variants, modestly increased promoter activity. If increased promoter activity translated into increased ABCC2 expression, then irinotecan and SN-38 exposure would be expected to be lower compared with patients with the reference sequence. However, ABCC2 À24C4T has been associated with increased irinotecan and SN-38 exposure, suggesting reduced transport of these substrates. 22, 29 Only limited studies have been previously carried out to characterize the functional impact of genetic polymorphisms in the ABCC2 promoter and 5 0 -UTR region. In cell-based reporter gene assays, the À24C4T/À1549G4A haplotype decreased promoter activity 39% 20 and the À24C4T variant alone caused a 20% reduction in promoter activity. 10 The reporter plasmids used in the current and previous studies contain different lengths of upstream DNA sequence, which may account for the varying results. In cell lines with different genotypes, the À24C4T polymorphism had no effect on DNA binding or mRNA stability but was associated with reduced protein expression and corresponding effects on transport function. 35 Consistent with these cell-based findings, À24C4T had no effect on the expression of ABCC2 mRNA in hippocampal, intestinal, placental or adenocarcinoma samples. 9,23,36--38 In contrast, lower levels of ABCC2 renal mRNA were reported in patients carrying the À24T allele. 10 In addition to associations of À24C4T with irinotecan and SN-38 exposure, this variant has also been associated with increased diclofenac hepatotoxicity, 21 greater risk of platinum hematological toxicity 31 and antiepileptic drug resistance, 36 and increased response to irinotecan and cisplatin treatment. 24 Most of these findings have not been replicated, and in the case of antiepileptic drug resistance, recent data refutes the original association. 39 A possible reason for the inconsistency between studies is that ABCC2 promoter SNPs previously associated with clinical phenotypes (for example, SN-38 pharmacokinetics and drug toxicities) are not causative and are in linkage disequilibrium with other SNPs (cis-or trans-acting) that are functional. In support of this alternative explanation, ENCODE data available on the UCSC genome browser indicate there are only two clusters of transcription factors binding in the ABCC2 promoter region and there is very little overlap of any SNPs previously associated with clinical phenotypes with this region. This publically available data are consistent with our findings that the commonly studied ABCC2 promoter SNPs are not critical for transcriptional regulation of ABCC2 and that other SNPs and transcriptional modulators may be responsible for variability in MRP2 expression and function. For example, trans-acting SNPs as well as epigenetic mechanisms may be involved in the regulation of ABCC2 expression. Further studies will be necessary to fully understand the functional and clinical impact of any of the ABCC2 promoter/UTR polymorphisms.
ABCC2 À24C4T is in linkage disequilibrium with a synonymous 3972C4T polymorphism, raising the possibility that previously reported associations of the 5 0 -UTR variant with clinical phenotypes may reflect functional changes related to the synonymous variant. In allelic imbalance studies, we found a significant preference for the 3972C allele compared with the 3972T allele. This appears to be driven by a haplotype (H2) that includes polymorphisms at À1549, À1019 and À24 in ABCC2, and H4 that includes only the À1549 and À1019 SNPs. The relative effect of the observed allelic imbalance is modest, with at most a 14% average increase in transcription of the 3972C allele compared with the T allele. However, a large degree of interindividual variability was observed in this measurement and up to 45% increases were measured. The allelic imbalance did not affect total hepatic or renal ABCC2 mRNA levels, suggesting its clinical significance will be limited except perhaps in individuals with extreme degrees of allele-specific expression.
A recent paper suggests that the 3972C4T variant could also be acting through a post-transcriptional mechanism. The À24C4T variant was associated with a modest decrease in MRP2 recombinant protein expression, while 3972C4T variant had much more profound effect and drove the observed decrease in protein expression with the À24T/3972T haplotype. 35 Interestingly, no effect on mRNA expression was observed, suggesting these polymorphisms have an important role in MRP2 translational regulation. The contribution of genetic variation to post-transcriptional regulation of ABCC2/MRP2 expression should be further explored. Additional mechanisms for regulation of ABCC2/MRP2, including expression quantitative trait loci and epigenetics, also warrant investigation. Interindividual variation in these mechanisms may contribute to variation in transport of endogenous and xenobiotic substrates of MRP2.
In summary, a number of common promoter and 5 0 -UTR polymorphisms in ABCC2 are found at relatively high frequency across different ethnic groups. The limited, if any, effect of these variants on promoter activity suggests that reported associations with clinical phenotypes are not a result of impaired transcription. The 3972C4T synonymous variant is associated with allelicspecific expression, although the magnitude of the effect is modest. Additional mechanisms will need to be explored to account for the reported association of ABCC2 promoter variants with irinotecan disposition and other drug response phenotypes.
